Sara M. Bonstein
Independent ChairmanMs. Sara M. Bonstein, MBA, serves as Independent Director at Latigo Biotherapeutics, Inc. since April 2026. She has vast executive and financial leadership experience across biotechnology companies. She joined Insmed in January 2020 and as its chief financial officer is responsible for key financial functions, including accounting, financial planning and analysis, procurement and investor relations. With more than two decades of operational and financial leadership in the life sciences industry, she has deep experience in raising capital and has raised more than 4 billion while establishing strong financial controls, streamlining business operations and building high-performing teams. Prior to joining Insmed, she served as the chief financial officer and chief operating officer at OncoSec Medical and as the chief financial officer at Advaxis, Inc. She also previously held positions of increasing responsibility at Eli Lilly & Company and Johnson & Johnson. She has been a Non-Employee Independent Director at Xilio Therapeutics, Inc., since August 2021 and serves as its Independent Chairman since January 06, 2026. She served as Chief Financial Officer at Insmed Incorporated since joining on January 31, 2020 until October 30, 2026. Ms. Bonstein serves as an Independent Director at scPharmaceuticals Inc. since July 2020. She served as Chief Financial Officer and Chief Operating Officer of OncoSec Medical Inc since May 2018 until January 30, 2020 and also served as its Company Secretary until January 2020. She was the Chief Financial Officer of Advaxis, Inc. since March 24, 2014 until April 30, 2018 and was its Executive Vice President since December 30, 2016. Ms. Bonstein served as Corporate Secretary and Principal Accounting Officer of Advaxis, Inc until April 30, 2018. Since March 2014, she served as Senior Vice President of Advaxis, Inc. She served as Secretary and Treasurer of Advaxis, Inc. since July 26, 2016 until October 11, 2016. From 2001 to 2004, Ms. Bonstein served in various roles at Johnson & Johnson. She has financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems Incorporated and Johnson & Johnson. While at Eli Lilly & Company, she was a Six Sigma Champion and Black Belt at Eli Lilly and Company (Lilly) from January 2012 to February 2014, leading multiple projects relating to clinical research, project management, finance, manufacturing and commercial sales. From August 2004 to December 2011, she held positions of increasing responsibility at ImClone (which was acquired by Eli Lilly in 2008) including Director of Development Finance where she led all budget and forecast activities for preclinical, clinical and manufacturing research and development, spanning over ten monoclonal antibody cancer therapeutics, including Erbitux. Ms. Bonstein was a Financial Analyst at Johnson & Johnson in both the Ortho McNeil Pharmaceuticals and Ortho Biotech Divisions. In 2016, NJBiz named Ms. Bonstein CFO of the Year – Healthcare Organization and Forty under 40. Ms. Bonstein is a 2004 graduate of Johnson & Johnson's Financial Leadership Development Program. She holds a BS in Finance from The College of New Jersey and an MBA from Rider University.
Positions
- Company NameXilio Therapeutics, Inc.Stock CodeXLOPositionIndependent ChairmanColleagues
- RRRene RussoPresident, CEO & Director
- CFChristopher FrankenfieldCFO & COO
- KMKevin M. BrennanSenior Vice President of Finance & Accounting
- UBUli BialuchaChief Scientific Officer
- NMNathan McBrideChief Information Officer
- DJDaniel J. CurranIndependent Director
- JSJames S. ShannonIndependent Director
- CRCheryl Renee BlanchardIndependent Director
- Company NameLatigo Biotherapeutics, Inc.Stock CodeLTGOPositionIndependent DirectorColleagues
- NKNeha KrishnamohanChief Business Officer & CFO
- TPTimothy P. WalbertIndependent Chairman
- NFNima FarzanExecutive Officer
- NKNeil Kumar SinglaChief Medical Officer
- TNTodd N. SmithPresIdent, CEO & Director
- JCJulia ChapmanSenior Vice President of Operations
- BCBeth C. SeidenbergIndependent Director
- SMSara M. BonsteinIndependent Director
- DPDeborah PalestrantIndependent Director
